.Attributes Medication, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of individuals with HER2+ state-of-the-art bosom cancer cells as well as energetic or secure human brain metastases showed consistent intracranial task and wide spread efficacy of T-DXd.